Use of vascular access ports with intrathoracic drains for treatment of pleural effusion in three dogs

CASE DESCRIPTION: 3 dogs (9 to 12 years old) were evaluated because of recurrent pleural effusion that was refractory to treatment of the underlying cause. CLINICAL FINDINGS: Dogs were evaluated because of cough, dyspnea, tachypnea, or lethargy or a combination of these clinical signs. Radiography, ultrasonography, or thoracocentesis were used to confirm the presence of pleural fluid in each dog. A neoplastic cause of pleural effusion was confirmed in 2 dogs. In 1 dog, fasciitis of the mediastinum and the left parietal pleura was diagnosed, with no evidence of neoplasia. TREATMENT AND OUTCOME: Each dog was anesthestized, and thoracotomy was performed with manual perforation of the mediastinum. Permanent, subcutaneously placed vascular access ports were attached to intrathoracic, Jackson-Pratt drain tubing for repeated drainage of pleural fluid. Drains were used successfully in the 3 dogs for periods of 6 weeks, 11 weeks, and > 3 years. CLINICAL RELEVANCE: Findings suggest that subcutaneous vascular access ports attached to intrathoracic drain tubing may be an effective way to remove recurrent pleural effusion in dogs.     

Use of vascular access ports in femoral veins of dogs and cats with cancer

OBJECTIVE: To evaluate long-term function of vascular access ports (VAPs) implanted in the femoral vein of dogs and cats undergoing cancer treatment. DESIGN: Prospective clinical study. ANIMALS: 3 dogs and 6 cats treated via chemotherapy or radiation. PROCEDURES: VAPs were surgically implanted in the left femoral vein of 3 dogs and 6 cats over a 1-year period. Injection port location was alternated to either a caudal thoracic or ilial location in each patient. Duration of VAP function, ease of infusion, and ease of aspiration through the VAPs were recorded, and associated complications were assessed at each VAP use. Client satisfaction with VAP placement was evaluated by use of a questionnaire. RESULTS: Primary uses of the VAPs included blood sampling and delivering sedative or chemotherapeutic drugs. Median duration of successful infusion was 147 days (range, 60 to 370 days), and median duration of successful aspiration was 117 days (range, 10 to 271 days). The frequency of signs of VAP-related discomfort was low (7% of patient observations). Clients were satisfied with their decision to use VAPs. Complications included partial (n = 7) or complete (2) VAP occlusion, port migration (1), and presumptive infection (1). CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that VAP implantation into the femoral vein provides an acceptable means of chronic venous access in dogs and cats undergoing cancer treatment.     

Cryosurgery for treatment of recurrent proliferative keratoconjunctivitis in five dogs

Cryosurgery was used for treatment of recurrent proliferative keratoconjunctivitis in 5 dogs that had been treated with combined medical and surgical procedures without success. Four dogs recovered completely after one application of cryosurgery. The fifth dog did not respond to cryosurgery until after oral administration of corticosteroids was stopped, indicating a possible immune-mediated mechanism of action of cryosurgery on proliferative keratoconjunctivitis.     

Complications associated with the use of vascular access ports in dogs receiving external beam radiation therapy

OBJECTIVE: To assess the perioperative and postoperative complications associated with use of vascular access ports (VAPs) in the jugular and lateral saphenous veins of dogs requiring frequent anesthetic episodes for radiation therapy. DESIGN: Cohort study. ANIMALS: 40 dogs referred to a veterinary teaching hospital. PROCEDURES: VAPs were used in 23 dogs, and intravenous catheters inserted in a peripheral vein were used in 17 dogs. The frequency of perioperative and postoperative complications associated with VAP use and the frequency of infection associated with intravenous catheter use were recorded. Results of bacterial culture of VAP tips and amount of time required for VAP placement and removal and for anesthetic induction were also recorded. RESULTS: VAP-associated perioperative complications included malposition of the catheter tip in 4 of 23 (17.4%) dogs. The VAP-associated postoperative complications included seroma formation in 7 (30.4%) dogs, breakage of port-anchoring sutures in 3 (13.0%) dogs, suspected fatal catheter-related septicemia in 1 (4.3%) dog, and temporary partial withdrawal occlusion in 18 of 255 (7.1%) anesthetic episodes. CONCLUSIONS AND CLINICAL RELEVANCE: Placement of VAPs provided ready access in dogs receiving radiation therapy. Most complications were minor and self-limiting; however, a low risk of serious complications existed. Use of fluoroscopy to assess position of the catheter tip is recommended to decrease the risk of malposition. Immediate removal of a VAP is recommended when clinical signs of infection develop. Removal of a VAP at the completion of radiation therapy should be performed unless the benefit of continued vascular access outweighs the risks.     

Use of lufenuron for treatment of generalized demodicosis in dogs

Abstract The efficacy of lufenuron for treatment of generalized demodicosis in dogs was investigated. Eleven dogs with generalized demodicosis received either low-dose lufenuron (mean 13.3 mg kg^-1 once a day on the first 5 days of the month) or high-dose lufenuron (mean 15.8 mg kg^-1 three times a week) orally for 2 or 3 months. None of the dogs showed a decrease in mite numbers on monthly examination of deep skin scrapings. To determine levels of orally administered lufenuron in the skin (epidermis and dermis), three adult dogs were each given lufenuron orally at a mean dose of 19.3 mg kg^-1 once a day for 5 days. Lufenuron was measured in samples of blood and skin collected on days 0, 1, 6, 16, 30, 44 and 60 after administering the drug. Mean skin levels of lufenuron were 10 times the corresponding blood levels. Lufenuron was ineffective as a treatment for generalized demodicosis in these dogs despite the fact that high drug levels were achieved in the skin. Résumé— L'efficacitée du Lufénuron dans le traitement de la démodécie généralisée du chien a étéévaluée 11 chiens présentant une démodécie généralisée ont reçu soit du lufeAnuron à dose faible (en moyenne 13, 3 mg kg^-1, 1 fois par jour les 5 premiers jours de chaque mois) ou à dose élevée (en moyenne 15, 8 mg kg^-1 fois par semaine) par voie orale pendant 2 à 3 mois. Aucun des chiens traités ne montre une diminution du nombre de parasites determine à partir de raclages cutanés profonds mensuels. Afin de déterminer les taux de lufénuron dans la peau (épiderme et derme), trois chiens adultes ont reçu chacun du lufénuron par voie orale à une dose moyenne de 19, 3 mg kg^-1, une fois par jour pendant 5 jours. Le lufénuron a été mesuré dans des échantillons sanguins et cutanés à JO, J1, J6, J16, J30, J44 et J60 après administration. Les taux moyens dans la peau sont 10 fois supérieurs aux taux sanguins correspondants. Le lufénuron est inefficace dans le traitement de la démodécie généralisée en dépit des concentrations élévées dans la peau. [Schwassmann, M., Kunkle, G. A., Hepler, D. I., Lewis, D. T. Use of lufénuron for treatment of generalized demodicosis in dogs. (Utilisation du Lufénuron pour le traitement de la démodécie généralisée du chien.) Veterinary Dermatology 1997; 8 : 11–18.] Resumen Se investigó la eficacia de lufénuron para el tratamiento de la demodicosis generalizada en perros. Once perros con demodicosis generalizada recibieron o bien una dosis baja de lufénuron (medía 13.3 mg kg^-1 una vez al día en los primeros 5 meses del mes) o una dosis alta de lufénuron (medía 15.8 mg kg^-1 3 veces a la semana) oralmente durante 2 o 3 meses. Ninguno de los perros mostró dismunición en el número de ácaros en los exámenes mensuales de raspados cutáneos profundos. Para detectar en la piel (epidermis y dermis) los niveles de lufénuron administrado oralmente, a tres perros adultos se les administró a cada uno lufénuron oral a una dosis medía de 19.3 mg kg^-1 una vez al día durante 5 días. Se cuantificó el lufénuron en muestras de sangre y piel tomadas a días 0, 1, 6, 16, 30, 44 y 60 después de la administración del fármaco. Los valores cutáneos medios de lufénuron fueron 10 veces los valores sanguineos correspondientes. Lufénuron no tuvo efecto como tratamiento de la demodicosis generalizada en estos perros a pesar de los altos niveles farmacológicos alcanzados a nivel cutáneo. [Schwassmann, M., Kunkle, G. A., Hepler, D. I., Lewis, D. T. Use of lufénuron for treatment of generalized demodicosis in dogs. (Uso de lufénuron para el tratamiento de la demodicosis generalizada en perros.) Veterinary Dermatology 1997; 8 : 11–18.] Zusammenfassung— Die Wirksamkeit von Luferunon in der Behandlung von generalisierter Demodikose wurde untersucht. Elf Hunde mit generalisierter Demodikose erhielten entweder eine niedrige (durchschnittlich 13.3 mg kg^-1 täglich an den ersten fünf Monatstagen) oder hohe Dosis Lufénuron (durchschnittlich 15.8 mg kg^-1 dreimal wöchentlich) oral für 2–3 Monate. Bei keinem Hund zeigte die monatliche Untersuchung von tiefen Hautgeschabseln eine Verminderung der Milbenanzahl. Um den Hautspiegel (Epidermis und Dermis) des oral verabreichten Lufénurons zu bestimmen, erhielten drei Hunde jeweils oral Lufénuron in einer Durchschnittsdosis von 19.3 mg kg^-1 täglich für 5 Tage. Lufénuron wurde in Serum-und Hautproben gemessen die vor und 1, 6, 16, 30, 44 und 60 Tage nach Beginn der Medikamenteneinnahme genommen wurden. Durchschnittliche Hautspiegel von Lufénuron waren zehn Mai so hoch wie die korrespondierenden Blutspiegel. Die Behandlung der generalisierten Demodikose mit Lufénuron war trotz der hohen Medikamentenkonzentration in der Haul unwirksam. [Schwassmann, M., Kunkle, G. A., Hepler, D. I., Lewis, D. T. Use of lufénuron for treatment of generalized demodicosis in dogs. (Die Verwendung von Lufénuron für die Behandlung der generalisierten Demodikose beim Hund.) Veterinary Dermatology 1997; 8 : 11–18.]     

Use of cisplatin for treatment of appendicular osteosarcoma in dogs

Nineteen dogs were treated for osteosarcoma of the appendicular skeleton. Eleven dogs treated by amputation and adjunctive cisplatin chemotherapy had a significantly longer (P less than 0.003) median survival time of 43 weeks (range, 20 to 108 weeks) than did 8 dogs whose median survival time was 14.5 weeks (range, 8 to 46 weeks) after amputation alone. All 11 dogs given cisplatin were evaluated for signs of drug toxicosis. Transient episodes of vomiting were recorded in 9 of 11 dogs. Additional toxic effects included gradual decreases in endogenous creatinine clearance in 3 dogs and thrombocytopenia in 1 dog. On the basis of prolonged survival times and minimal adverse effects, we concluded that cisplatin has promise as an effective and relatively nontoxic agent, when combined with amputation, for treatment of dogs with osteosarcoma of the appendicular skeleton.     

Ultrasound-guided percutaneous drainage for treatment of pyonephrosis in two dogs

Pyonephrosis refers to suppurative destruction of the parenchyma of the kidney with complete or nearly complete loss of renal function. In dogs, nephrectomy is still the most common treatment for pyonephrosis; however, in the present report, a method for percutaneous ultrasound-guided drainage of the renal pelvis in dogs with pyonephrosis that does not require local or general anesthesia was described, and results of the procedure in 2 dogs were reported. Briefly, dogs were positioned in lateral recumbency with the affected side up, and skin overlying the affected kidney was aseptically prepared. The dilated renal pelvis was punctured percutaneously, under ultrasound guidance, with a 22-gauge needle, and a sample of material was obtained for analysis. The needle was then replaced with an IV catheter, and as much pus as possible was removed from the renal collecting system. A povidone iodine solution was then used to lavage the renal pelvis. Ultrasound-guided drainage and lavage of the renal pelvis was repeated daily until the renal pelvis was so small that it could no longer be punctured. Both dogs recovered and were reported by the owners to be healthy after the procedure.     

Catheter drainage of pleural fluid collections and pneumothorax

A technique for virtually atraumatic placement of small size chest catheters for suction drainage of pleural effusions and pneumothorax in the dog and cat is described. Thirty-nine dogs and two cats were treated for pyothorax (10 cases), hydrothorax (eight). chylothorax (three), haemothorax (three), haemothorax/pneumothorax (three) and pneumothorax (14). In all 41 cases, thin or viscous fluid and/or air were efficiently drained. The mean period of drainage was four days (range, 0.5 to 18 days). The average amount of fluid removed from each patient in 24 hours was 530 ml in pyothorax cases (range, 140 to 1100 ml) and 1300 ml in the other cases (range, 20 to 5000 ml). In 40 cases there were no complications related to the procedure. One dog with severe pleural adhesions was euthanased because of lung perforation and pneumothorax secondary to misplacement of the catheter.     

High-frequency jet ventilation during pneumothorax in dogs

Pneumothorax (45 ml of N/kg of body weight insufflated into the pleural space) in anesthetized dogs ventilated with air caused a significant (P less than 0.05) increase in pleural pressure, central venous pressure, capillary wedge pressure, and venous admixture. Cardiac index (CI) and arterial O2 tensions were decreased. Ventilation with 100% O2 increased arterial O2 tensions, but did not affect calculated intrapulmonary shunting of blood or CI. Application of 10 cm of H2O-positive end-expiratory pressure in the presence of pneumothorax during positive-pressure ventilation and high-frequency jet ventilation reduced intrapulmonary shunting of blood, which remained higher than control values, and caused a further decrease in CI. Cardiopulmonary function during pneumothorax in anesthetized dogs was more profoundly affected by the application of positive end-expiratory pressure than by the form of mechanical ventilation.     

Surgical treatment for multiple lesions of elbow dysplasia in two dogs

The presence of an ununited coronoid process, an ununited anconeal process and an ectopic proximolateral radial ossification center are described in a single elbow joint of a ten month old unspayed Great Dane. This animal and a nine month old spayed Saint Bernard, also with an ununited coronoid process, both had marked degenerative osteoarthritis associated with the instabilities.

Chronic lameness and significant palpable elbow joint enlargement(s) were apparent in both dogs. Radiography was used to identify the lesions and surgical treatment produced satisfactory remission of signs.

     

Percutaneous balloon pericardiotomy as a treatment for recurrent pericardial effusion in 6 dogs

Percutaneous balloon pericardiotomy (PBP) has been performed in people and in a small number of dogs as a treatment for recurrent pericardial effusion with tamponade (PET). We performed this technique on 6 dogs with recurrent PET (5 with heart base tumors and 1 with no identifiable mass). Under general anesthesia and fluoroscopic guidance, a balloon-dilating catheter (diameters 14-20 mm) was introduced percutaneously at the 5th intercostal space through a sheath-introducing catheter, positioned across the parietal pericardium, and inflated 3 times. No dog experienced serious complications. The procedure was considered successful in 4 of 6 dogs. One dog is still alive without recurrence of PET 1 year after the procedure. Three dogs died of unrelated disease without recurrence of PET 5. 19, and 32 months after the procedure. The procedure was not beneficial in 1 dog that was euthanized 9 weeks later because of recurrence of pleural and abdominal effusion thought to be secondary to PET. One dog may have temporarily benefited but developed symptomatic PET 6 months after PBP. PBP appears to be a safe, economical, and potentially effective palliative treatment for recurrent PET and is a reasonable, less invasive alternative to surgery for dogs with recurrent PET, especially effusions caused by heart base tumors and possibly idiopathic pericardial effusion. Premature closure of the stoma is a potential cause for long-term failure and was thought to have been responsible for the recurrence of clinical signs in 2 dogs.     

Strategies for management of recurrent pyoderma in dogs

Staphylococcal skin infection (pyoderma) is a common clinical problem in dogs. The infection can be either superficial or deep. Most cases of staphylococcal pyoderma occur secondary to a definable underlying cause. Treatment consists of finding the underlying cause and correcting it, if possible, and treating the pyoderma with antibiotics. Antibacterial shampoos may be used as adjunct treatment, but corticosteroid drugs should not be used. When canine pyoderma recurs in the absence of an identifiable underlying cause, several treatment strategies can be effective in eliminating recurrence or limiting its severity. Frequent antibacterial shampoos are an easy and sometimes effective method. Immunomodulatory drugs are variably effective. Some commercially available bacterins are clearly helpful in treating recurrent pyoderma. As a last resort, the clinician may opt to keep the patient on long-term antibiotic therapy. Such therapy may promote development and dissemination of resistant strains of Staphylococcus and should be used only if absolutely necessary.     

Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs

The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla. A spiral fracture associated with the tibial tumour healed after it was stabilised with an external skeletal fixator. Both dogs remained comfortable and survived for 12 and 10 months respectively after diagnosis, despite the fact that neither primary tumour was resected.     

The use of vascular access ports for blood collection in feline blood donors

We investigated vascular access ports for feline blood donation. Eight cats were anesthetized for conventional blood collection by jugular venipuncture at the beginning and end of the study. In-between conventional collections, vascular access ports were used for collection with or without sedation every 6 to 8 wk for 6 mo. Ports remained functional except for one catheter breakage, but intermittent occlusions occurred. Systolic blood pressure was lower during conventional collection. Behavioral abnormalities occurred during 3 port collections. Packed red cells prepared from collected blood were stored at 4°C for 25 d and assessed for quality pre- and post-storage. With both collection methods, pH and glucose level declined, and potassium level, lactate dehydrogenase activity and osmotic fragility increased. There were no differences between methods in pre-storage albumin and HCO(3)(-) levels, and pre and post-storage hematocrit, lactate dehydrogenase activity, and glucose and potassium levels. Pre-storage pH and pCO(2) were higher with conventional collection, and pre- and post-storage osmotic fragility were greater with port collection. One port became infected, but all cultures of packed red cells were negative. Tissue inflammation was evident at port removal. In a second study of conventional collection in 6 cats, use of acepromazine in premedication did not exacerbate hypotension. The use of vascular access ports for feline blood donation is feasible, is associated with less hypotension, and may simplify donation, but red cell quality may decrease, and effects on donors must be considered.     

Use of canine small intestinal submucosa allograft for treating perineal hernias in two dogs

Here, we describe two dogs in which canine small intestinal submucosa (SIS) was implanted as a biomaterial scaffold during perineal herniorrhaphy. Both dogs had developed severe muscle weakness, unilaterally herniated rectal protrusions, and heart problems with potential anesthetic risks. Areas affected by the perineal hernia (PH) located between the internal obturator and external anal sphincter muscles were reconstructed with naïve canine SIS sheets. In 12 months, post-operative complications such as wound infections, sciatic paralysis, rectal prolapse, or recurrence of the hernia were not observed. Symptoms of defecatory tenesmus also improved. Neither case showed any signs of rejection or specific immune responses as determined by complete and differential cell counts. Our findings demonstrate that canine SIS can be used as a biomaterial scaffold for PH repair in dogs.